- Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
- Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
- Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
- Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
- Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
- Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
- Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
- Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
- Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
More ▼
Key statistics
As of last trade, Allarity Therapeutics Inc (ALLR:NAQ) traded at 0.6068, 10.33% above the 52 week low of 0.55 set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.593 |
---|---|
High | 0.6214 |
Low | 0.578 |
Bid | 0.600 |
Offer | 0.6068 |
Previous close | 0.616 |
Average volume | 4.23m |
---|---|
Shares outstanding | 17.61m |
Free float | 17.61m |
P/E (TTM) | -- |
Market cap | 10.85m USD |
EPS (TTM) | -599.34 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 17:05 BST.
More ▼